Skip to content
Biodatica
Start free

Bristol-Myers Squibb

London, Utah

Oncologycell therapyFiled/ApprovedListed · BMY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

4d agoTrial registeredJul 15, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Sep 30, 2026

    Non-Small Cell Lung Cancer · NOT_YET_RECRUITING · sponsor: Bristol-Myers Squibb · Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

    ClinicalTrials.gov · NCT07680790 (opens the source filing in a new tab)

  2. Trial

    Study registered

    May 24, 2026

    Non-Small Cell Lung Cancer · NOT_YET_RECRUITING · sponsor: Bristol-Myers Squibb · Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

    ClinicalTrials.gov · NCT07599007 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Apr 27, 2026

    Healthy Participants · RECRUITING · sponsor: Bristol-Myers Squibb · A Phase 1 Study of Navlimetostat Tablet Formulations

    ClinicalTrials.gov · NCT07544628 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Mar 25, 2026

    Alzheimer Disease, Psychosis · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

    ClinicalTrials.gov · NCT06947941 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Mar 16, 2026

    Non-small Cell Lung Cancer (NSCLC) · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

    ClinicalTrials.gov · NCT07361497 (opens the source filing in a new tab)

  6. Trial

    PHASE2/PHASE3 registered

    Mar 13, 2026

    Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

    ClinicalTrials.gov · NCT07221149 (opens the source filing in a new tab)

  7. Trial

    PHASE3 registered

    Mar 12, 2026

    Non-Small Cell Lung Cancer (NSCLC) · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

    ClinicalTrials.gov · NCT07361510 (opens the source filing in a new tab)

  8. Trial

    Study registered

    Feb 27, 2026

    AVAILABLE · sponsor: Bristol-Myers Squibb · Expanded Access for Iberdomide

    ClinicalTrials.gov · NCT07434960 (opens the source filing in a new tab)

  9. Trial

    Study registered

    Feb 26, 2026

    Schizophrenia · RECRUITING · sponsor: Bristol-Myers Squibb · Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

    ClinicalTrials.gov · NCT07379827 (opens the source filing in a new tab)

  10. Trial

    Study registered

    Feb 2, 2026

    Lower-risk Myelodysplastic Syndromes (TD LR-MDS) · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

    ClinicalTrials.gov · NCT07465029 (opens the source filing in a new tab)

  11. Trial

    Study registered

    Jan 15, 2026

    Hypertrophic Cardiomyopathy · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

    ClinicalTrials.gov · NCT07361289 (opens the source filing in a new tab)

  12. Trial

    PHASE1 registered

    Dec 31, 2025

    Healthy Volunteers · COMPLETED · sponsor: Bristol-Myers Squibb · Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

    ClinicalTrials.gov · NCT07223671 (opens the source filing in a new tab)

  13. Trial

    PHASE2/PHASE3 registered

    Nov 5, 2025

    Non-Small Cell Lung Cancer · RECRUITING · sponsor: Bristol-Myers Squibb · Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    ClinicalTrials.gov · NCT07100080 (opens the source filing in a new tab)

  14. Trial

    PHASE2/PHASE3 registered

    Oct 23, 2025

    Pancreatic Ductal Adenocarcinoma · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

    ClinicalTrials.gov · NCT07076121 (opens the source filing in a new tab)

  15. Trial

    PHASE2/PHASE3 registered

    Sep 30, 2025

    Urothelial Cancer · RECRUITING · sponsor: Bristol-Myers Squibb · Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

    ClinicalTrials.gov · NCT07106762 (opens the source filing in a new tab)

  16. Trial

    PHASE2/PHASE3 registered

    Sep 11, 2025

    Breast Neoplasms · RECRUITING · sponsor: Bristol-Myers Squibb · A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

    ClinicalTrials.gov · NCT06926868 (opens the source filing in a new tab)

  17. Trial

    PHASE4 registered

    Sep 4, 2025

    Symptomatic Obstructive Hypertrophic Cardiomyopathy · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

    ClinicalTrials.gov · NCT07004972 (opens the source filing in a new tab)

  18. Trial

    Study registered

    Aug 26, 2025

    Advanced Cancer, Metastatic Cancer, Malignant Neoplasm · APPROVED_FOR_MARKETING · sponsor: Bristol-Myers Squibb · Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

    ClinicalTrials.gov · NCT05162443 (opens the source filing in a new tab)

  19. Trial

    PHASE1 registered

    Aug 1, 2025

    Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer · RECRUITING · sponsor: Bristol-Myers Squibb · A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    ClinicalTrials.gov · NCT06997029 (opens the source filing in a new tab)

  20. Trial

    PHASE3 registered

    Jul 14, 2025

    Alzheimer's Disease · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

    ClinicalTrials.gov · NCT06976216 (opens the source filing in a new tab)

  21. Trial

    PHASE3 registered

    Jun 11, 2025

    Bipolar-I Disorder With Mania or Mania With Mixed Features · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

    ClinicalTrials.gov · NCT06951698 (opens the source filing in a new tab)

  22. Trial

    Study registered

    May 21, 2025

    Obstructive Hypertrophic Cardiomyopathy (oHCM) · RECRUITING · sponsor: Bristol-Myers Squibb · Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

    ClinicalTrials.gov · NCT07383025 (opens the source filing in a new tab)

  23. Trial

    Study registered

    May 13, 2025

    Myelodysplastic Syndrome (MDS) · COMPLETED · sponsor: Bristol-Myers Squibb · Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan

    ClinicalTrials.gov · NCT07008820 (opens the source filing in a new tab)

  24. Trial

    PHASE1 registered

    Feb 27, 2025

    Healthy Volunteers · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

    ClinicalTrials.gov · NCT06846866 (opens the source filing in a new tab)

  25. Trial

    PHASE1/PHASE2 registered

    Feb 12, 2025

    Advanced Solid Tumors · RECRUITING · sponsor: Bristol-Myers Squibb · A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

    ClinicalTrials.gov · NCT06730750 (opens the source filing in a new tab)

  26. Trial

    Study registered

    Dec 23, 2024

    Relapsed/Refractory Multiple Myeloma · COMPLETED · sponsor: Bristol-Myers Squibb · Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens

    ClinicalTrials.gov · NCT07689006 (opens the source filing in a new tab)

  27. Trial

    Study registered

    Dec 10, 2024

    Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France

    ClinicalTrials.gov · NCT06504615 (opens the source filing in a new tab)

  28. Trial

    Study registered

    Nov 25, 2024

    Non-small Cell Lung Cancer (NSCLC) · RECRUITING · sponsor: Bristol-Myers Squibb · Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

    ClinicalTrials.gov · NCT06448793 (opens the source filing in a new tab)

  29. Trial

    Study registered

    Nov 1, 2024

    Myelodysplastic Syndromes · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept

    ClinicalTrials.gov · NCT07075406 (opens the source filing in a new tab)

  30. Trial

    PHASE1 registered

    Oct 7, 2024

    Healthy Participants · COMPLETED · sponsor: Bristol-Myers Squibb · Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants

    ClinicalTrials.gov · NCT06566768 (opens the source filing in a new tab)

  31. Trial

    PHASE1 registered

    Sep 19, 2024

    Healthy Participants · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

    ClinicalTrials.gov · NCT06568458 (opens the source filing in a new tab)

  32. Trial

    Study registered

    Aug 21, 2024

    β-Thalassemia Major · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan

    ClinicalTrials.gov · NCT06596642 (opens the source filing in a new tab)

  33. Trial

    PHASE4 registered

    Jun 24, 2024

    Healthy Volunteers · COMPLETED · sponsor: Bristol-Myers Squibb · A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

    ClinicalTrials.gov · NCT06476834 (opens the source filing in a new tab)

  34. Trial

    Study registered

    Jun 24, 2024

    Obstructive Hypertrophic Cardiomyopathy (oHCM) · COMPLETED · sponsor: Bristol-Myers Squibb · Real-World Effectiveness of Mavacamten in Canada

    ClinicalTrials.gov · NCT06338202 (opens the source filing in a new tab)

  35. Trial

    Study registered

    Apr 5, 2024

    Peripheral T-cell Lymphoma · COMPLETED · sponsor: Bristol-Myers Squibb · Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

    ClinicalTrials.gov · NCT06422247 (opens the source filing in a new tab)

  36. Trial

    PHASE3 registered

    Dec 21, 2023

    Carcinoma, Non-Small-Cell Lung · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

    ClinicalTrials.gov · NCT06140836 (opens the source filing in a new tab)

  37. Trial

    Study registered

    Dec 6, 2023

    Hypertrophic Cardiomyopathy · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan

    ClinicalTrials.gov · NCT06181617 (opens the source filing in a new tab)

  38. Trial

    Study registered

    Nov 9, 2023

    Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related · RECRUITING · sponsor: Bristol-Myers Squibb · Mavacamten Pregnancy Surveillance Program

    ClinicalTrials.gov · NCT05939700 (opens the source filing in a new tab)

  39. Trial

    PHASE2 registered

    Nov 7, 2023

    Heart Failure · RECRUITING · sponsor: Bristol-Myers Squibb · Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

    ClinicalTrials.gov · NCT06122779 (opens the source filing in a new tab)

  40. Trial

    Study registered

    Oct 11, 2023

    Non-small Cell Lung Cancer (NSCLC) · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    ClinicalTrials.gov · NCT06487156 (opens the source filing in a new tab)

  41. Trial

    Study registered

    Oct 6, 2023

    Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma · RECRUITING · sponsor: Bristol-Myers Squibb · Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

    ClinicalTrials.gov · NCT06357754 (opens the source filing in a new tab)

  42. Trial

    PHASE3 registered

    Sep 14, 2023

    Idiopathic Pulmonary Fibrosis · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

    ClinicalTrials.gov · NCT06003426 (opens the source filing in a new tab)

  43. Trial

    Study registered

    Aug 29, 2023

    Cancer, Solid Tumors · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home

    ClinicalTrials.gov · NCT06163053 (opens the source filing in a new tab)

  44. Trial

    PHASE3 registered

    Jun 22, 2023

    Multiple Myeloma · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

    ClinicalTrials.gov · NCT05827016 (opens the source filing in a new tab)

  45. Trial

    PHASE4 registered

    Jun 5, 2023

    Anemia · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

    ClinicalTrials.gov · NCT05891249 (opens the source filing in a new tab)

  46. Trial

    PHASE3 registered

    Jan 10, 2023

    Relapsed or Refractory Multiple Myeloma · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

    ClinicalTrials.gov · NCT05552976 (opens the source filing in a new tab)

  47. Trial

    PHASE2/PHASE3 registered

    Dec 14, 2022

    Myelodysplastic Syndromes · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

    ClinicalTrials.gov · NCT05469737 (opens the source filing in a new tab)

  48. Trial

    PHASE2 registered

    Aug 19, 2022

    Leukemia, Myeloid, Acute · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission

    ClinicalTrials.gov · NCT05413018 (opens the source filing in a new tab)

  49. Trial

    Study registered

    Jun 29, 2022

    Stomach Neoplasms · COMPLETED · sponsor: Bristol-Myers Squibb · A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer

    ClinicalTrials.gov · NCT05334719 (opens the source filing in a new tab)

  50. Trial

    PHASE1 registered

    Dec 10, 2021

    Multiple Sclerosis (MS) · TERMINATED · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

    ClinicalTrials.gov · NCT05064436 (opens the source filing in a new tab)

  51. Trial

    PHASE2 registered

    Mar 17, 2021

    Extensive-stage Small Cell Lung Cancer · COMPLETED · sponsor: Bristol-Myers Squibb · A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

    ClinicalTrials.gov · NCT04702880 (opens the source filing in a new tab)

  52. Trial

    Study registered

    Sep 28, 2020

    Lung Cancer · COMPLETED · sponsor: Bristol-Myers Squibb · A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy

    ClinicalTrials.gov · NCT04500535 (opens the source filing in a new tab)

  53. Trial

    PHASE1 registered

    Jul 20, 2020

    Healthy Participants · COMPLETED · sponsor: Bristol-Myers Squibb · Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

    ClinicalTrials.gov · NCT04470778 (opens the source filing in a new tab)

  54. Trial

    PHASE3 registered

    Sep 30, 2019

    Hepatocellular Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

    ClinicalTrials.gov · NCT04039607 (opens the source filing in a new tab)

  55. Trial

    PHASE2/PHASE3 registered

    Sep 27, 2018

    Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy · COMPLETED · sponsor: Bristol-Myers Squibb · A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

    ClinicalTrials.gov · NCT03723655 (opens the source filing in a new tab)

  56. Trial

    Study registered

    May 12, 2017

    Head and Neck Cancer · COMPLETED · sponsor: Bristol-Myers Squibb · Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy

    ClinicalTrials.gov · NCT03114163 (opens the source filing in a new tab)

  57. Trial

    PHASE3 registered

    Mar 4, 2017

    Non Small Cell Lung Cancer · COMPLETED · sponsor: Bristol-Myers Squibb · A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

    ClinicalTrials.gov · NCT02998528 (opens the source filing in a new tab)

  58. Trial

    PHASE2 registered

    Jul 15, 2016

    Multiple Myeloma · COMPLETED · sponsor: Bristol-Myers Squibb · Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

    ClinicalTrials.gov · NCT02719613 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources